I’ve been following 24 stem cell stocks for a few years. I haven’t invested in them or any others recently, but rather just find them interesting. How are these doing in 2023? Mostly not great. In some cases, it is downright disastrous. Let’s take a quick look at four stocks very much in the news over […]
There has been a steady stream of encouraging data on stem cells for MS. Particularly for certain kinds of MS. A new study adds to this upbeat direction. Good news on stem cells for MS Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study, Journal of Neurology, Neurosurgery,
Weekly reads: stem cells for MS, Kimera Labs IND, FDA lawsuit Read More »
BrainStorm Cell Therapeutics is developing Nurown, an investigational therapy intended for treating ALS. I recently posted about BrainStorm and its prospects for providing real hope on stem cells for ALS. I see it as a long shot. The ALS community needs real hope, but one challenge is determining how good clinical data have to be to
BrainStorm Cell Therapeutics Hail Mary with FDA on Nurown for ALS Read More »
It feels like we are marching towards a future in which key aspects of human reproduction, including the use of artificial wombs, could be substantially different than for most of history. The FDA is considering allowing a clinical trial for use of artificial wombs in people. Human trials of artificial wombs could start soon. Here’s
Weekly reads: artificial wombs, mice with rat brains, Neuralink Read More »
Retraction Watch has been a great resource for those of us who have been following research misconduct. They widely cover and conduct research on retractions, corrections, and other developments in this space. Unfortunately, there’s been plenty to write about even just within the stem cell and cell therapy arena, which is my primary interest. Think
Several groups including Viviane Tabar who is a founding scientist at BlueRock Therapeutics are moving forward on potential cell therapies for Parkinson’s Disease. BlueRock just released some new data that’s worth a look. Check out the new BlueRock poster. In today’s post, I briefly discuss the new data. I also go into the larger context
Small positive step for BlueRock Therapeutics Stem Cell Therapy for Parkinson’s Read More »
It’s great finding stem cell videos on YouTube that are either excellent research talks or provide important information. I recently found one such video by Shiri Gur-Cohen, which I included below. Interesting data there and Shiri is such a compelling speaker. She also won The Niche image contest one year with a cool microscopy pic
Weekly stem cell reads: Google Bard AI issues, fat ball reprogramming, BrainStorm on ALS Read More »
So many things have gotten very expensive these days that it got me thinking this past week again about stem cell cost. For this reason, I’ve been running polls asking people what they’ve paid for stem cells and how many therapies they’ve gotten. Before jumping into our weekly reads, check out those running polls on
Weekly reads: stem cell cost, trial death, HSCT for MS, Neuralink Read More »
I’ve written before about Liz Parrish and her life-extension firm BioViva. Now they appear to have connections with another entity called Integrated Health Systems or IHS, according to a new Wired article. Some of what is going on with IHS and maybe BioViva in Mexico seems extremely risky to me. BioViva, Parrish, and Integrated Health Systems The
Weekly reads: BioViva & life-extension clinic, RMATs, universal cells Read More »
I’ve been writing The Niche now for more than 13 years and the idea of stem cells for ALS has been around that whole time. Unfortunately, it has been slow going on this front, but there are still reasons for hope. Probably now much more than ever before. I’ll start with news on one path
Weekly reads: stem cells for ALS, cell wrinkles, editors quit Read More »